The median number of mutations detected in 17 patients with de novo BCR::ABL1+ AML was 2 (IQR, 1–3) vs. 1 (IQR, 0–2) in 19 CML-BP patients (p = 0.108). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.